Citius Oncology shares surge 19.71% after-hours after launching LYMPHIR, a novel CTCL immunotherapy.

Citius Oncology (CTOR) surged 19.71% in after-hours trading following the U.S. commercial launch of LYMPHIR, a novel FDA-approved immunotherapy for cutaneous T-cell lymphoma (CTCL). The drug, the first systemic CTCL treatment in over seven years, demonstrated a 36.2% objective response rate in pivotal trials and is now available nationwide through specialty distributors. The company highlighted LYMPHIR’s rapid efficacy, inclusion in NCCN guidelines, and a $400 million market opportunity, with potential international expansion. Strategic partnerships with Cardinal Health and McKesson further bolster commercialization efforts, while the permanent J-code facilitates reimbursement. The launch marks Citius Oncology’s first marketed product and is positioned as a value-driving catalyst for shareholders, aligning with the stock’s significant post-announcement rally.